Detailed information for compound 40584
Basic information
Technical information
- TDR Targets ID: 40584
- Name: 3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-c arboxylic acid
- MW: 302.11 | Formula: C12H9Cl2NO4
-
H donors: 3
H acceptors: 4
LogP: 2.92
Rotable bonds: 4
Rule of 5 violations (Lipinski): 1 - SMILES: OC(=O)CCc1c([nH]c2c1c(Cl)cc(c2)Cl)C(=O)O
- InChi: 1S/C12H9Cl2NO4/c13-5-3-7(14)10-6(1-2-9(16)17)11(12(18)19)15-8(10)4-5/h3-4,15H,1-2H2,(H,16,17)(H,18,19)
- InChiKey: KNBSYZNKEAWABY-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- Maybridge3_007017
- SEW 06645
- Biomol-NT_000207
- IDI1_018404
- Oprea1_596892
- BPBio1_001266
- NCGC00163269-01
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Sus scrofa | Fructose-1,6-bisphosphatase | Starlite/ChEMBL | References |
| Rattus norvegicus | Glutamate NMDA receptor | Starlite/ChEMBL | References |
| Rattus norvegicus | Glutamate (NMDA) receptor subunit zeta 1 | Starlite/ChEMBL | References |
| Rattus norvegicus | Glutamate [NMDA] receptor subunit epsilon 3 | Starlite/ChEMBL | References |
| Homo sapiens | G protein-coupled receptor 17 | Starlite/ChEMBL | References |
| Homo sapiens | fructose-1,6-bisphosphatase 1 | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0378 | 0.6093 | 1 |
| Plasmodium vivax | ataxin-2 like protein, putative | 0.0092 | 0.0623 | 0.5 |
| Loa Loa (eye worm) | MH2 domain-containing protein | 0.0212 | 0.2913 | 0.4186 |
| Echinococcus multilocularis | geminin | 0.0159 | 0.191 | 0.231 |
| Chlamydia trachomatis | glutamine binding protein | 0.0069 | 0.0183 | 0.5 |
| Chlamydia trachomatis | arginine ABC transporter substrate-binding protein ArtJ | 0.0069 | 0.0183 | 0.5 |
| Echinococcus granulosus | geminin | 0.0159 | 0.191 | 0.231 |
| Brugia malayi | hypothetical protein | 0.0092 | 0.0623 | 0.1023 |
| Schistosoma mansoni | memapsin-2 (A01 family) | 0.0479 | 0.8015 | 1 |
| Leishmania major | 0.0378 | 0.6093 | 1 | |
| Treponema pallidum | amino acid ABC transporter, periplasmic binding protein (hisJ) | 0.0069 | 0.0183 | 0.5 |
| Mycobacterium ulcerans | flavin-containing monoamine oxidase AofH | 0.0582 | 1 | 1 |
| Trypanosoma cruzi | sedoheptulose-1,7-bisphosphatase, putative | 0.0141 | 0.1553 | 0.1699 |
| Toxoplasma gondii | fructose-bisphospatase I | 0.0141 | 0.1553 | 0.1699 |
| Schistosoma mansoni | hypothetical protein | 0.0159 | 0.191 | 0.1707 |
| Echinococcus granulosus | fructose 16 bisphosphatase 1 | 0.0378 | 0.6093 | 1 |
| Plasmodium falciparum | ataxin-2 like protein, putative | 0.0092 | 0.0623 | 0.5 |
| Echinococcus granulosus | nmda type glutamate receptor | 0.0191 | 0.2519 | 0.3429 |
| Echinococcus granulosus | glutamate receptor NMDA | 0.0095 | 0.0686 | 0.0059 |
| Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0378 | 0.6093 | 1 |
| Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 3 | 0.0096 | 0.0698 | 0.0081 |
| Treponema pallidum | amino acid ABC transporter, periplasmic binding protein | 0.0069 | 0.0183 | 0.5 |
| Echinococcus granulosus | nmda type glutamate receptor | 0.0109 | 0.095 | 0.0544 |
| Brugia malayi | MH2 domain containing protein | 0.0212 | 0.2913 | 0.4781 |
| Brugia malayi | fructose-1,6-bisphosphatase | 0.0378 | 0.6093 | 1 |
| Echinococcus multilocularis | nmda type glutamate receptor | 0.0109 | 0.095 | 0.0544 |
| Echinococcus multilocularis | glutamate receptor NMDA | 0.0095 | 0.0686 | 0.0059 |
| Echinococcus multilocularis | nmda type glutamate receptor | 0.0191 | 0.2519 | 0.3429 |
| Schistosoma mansoni | hypothetical protein | 0.0159 | 0.191 | 0.1707 |
| Toxoplasma gondii | fructose-bisphospatase II | 0.0378 | 0.6093 | 1 |
| Schistosoma mansoni | glutamate receptor NMDA | 0.0136 | 0.1464 | 0.1101 |
| Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.0378 | 0.6093 | 1 |
| Trypanosoma brucei | sedoheptulose-1,7-bisphosphatase | 0.0141 | 0.1553 | 0.1699 |
| Trypanosoma cruzi | sedoheptulose-1,7-bisphosphatase, putative | 0.0141 | 0.1553 | 0.1699 |
| Toxoplasma gondii | sedoheptulose-1,7-bisphosphatase | 0.0141 | 0.1553 | 0.1699 |
| Loa Loa (eye worm) | fructose-1,6-bisphosphatase | 0.0378 | 0.6093 | 1 |
| Schistosoma mansoni | fructose-16-bisphosphatase-related | 0.0378 | 0.6093 | 0.7388 |
| Echinococcus multilocularis | fructose 1,6 bisphosphatase 1 | 0.0378 | 0.6093 | 1 |
| Plasmodium falciparum | ataxin-2 like protein, putative | 0.0092 | 0.0623 | 0.5 |
| Loa Loa (eye worm) | transcription factor SMAD2 | 0.0212 | 0.2913 | 0.4186 |
| Mycobacterium tuberculosis | Probable flavin-containing monoamine oxidase AofH (amine oxidase) (MAO) | 0.0541 | 0.9216 | 1 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Activity (binding) | = 100 % | Agonist activity at recombinant human GPR17 short isoform transfected in human 1321N1 cells assessed as mobilization of intracellular Ca2+ at 0 | PATENT. | No reference |
| Activity (binding) | = 100 % | Agonist activity at recombinant human GPR17 short isoform transfected in CHO cells assessed as mobilization of intracellular Ca2+ at 0 | PATENT. | No reference |
| Animals protected (functional) | = 0 | In vivo activity in DBA/2 Mouse audiogenic seizure model was determined by testing number of animals protected after a dose of 50 mg/Kg i.p.; Number of animals tested 8 mice | ChEMBL. | No reference |
| Animals protected (functional) | = 6 | In vivo activity in DBA/2 Mouse audiogenic seizure model was determined by testing number of animals protected after a dose of 100 mg/Kg i.p.; Number of animals tested 8 mice | ChEMBL. | No reference |
| Animals protected (functional) | = 0 | In vivo activity in DBA/2 Mouse audiogenic seizure model was determined by testing number of animals protected after a dose of 50 mg/Kg i.p.; Number of animals tested 8 mice | ChEMBL. | No reference |
| Animals protected (functional) | = 6 | In vivo activity in DBA/2 Mouse audiogenic seizure model was determined by testing number of animals protected after a dose of 100 mg/Kg i.p.; Number of animals tested 8 mice | ChEMBL. | No reference |
| EC50 (binding) | = 6.09 | Agonist activity at recombinant human GPR17 short isoform transfected in human 1321N1 cells assessed as mobilization of intracellular Ca2+ after 20 mins by oregon green 488 BAPTA-1/AM dye-based fluorescence assay | PATENT. | No reference |
| EC50 (binding) | = 8.2 | Agonist activity at recombinant human GPR17 short isoform transfected in CHO cells assessed as mobilization of intracellular Ca2+ after 20 mins by oregon green 488 BAPTA-1/AM dye-based fluorescence assay | PATENT. | No reference |
| EC50 (functional) | = 0.331 uM | Agonist activity at human GPR17 receptor transfected in 1321N1 astrocytoma cells assessed as induction of intracellular calcium mobilization by fluorimetric assay | ChEMBL. | No reference |
| ED50 (functional) | = 1.5 mg kg-1 | The compound was evaluated in vivo for the anticonvulsant activity in quinolinic acid seizure model (intracerebroventricular), for 5 min drug pretreatment time | ChEMBL. | 1534125 |
| ED50 (functional) | = 1.5 mg kg-1 | The compound was evaluated in vivo for the anticonvulsant activity in quinolinic acid seizure model (intracerebroventricular), for 5 min drug pretreatment time | ChEMBL. | 1534125 |
| ED50 (functional) | > 50 mg kg-1 | The compound was evaluated in vivo for the anticonvulsant activity in quinolinic acid seizure model (intravenous), for 5 min drug pretreatment time | ChEMBL. | 1534125 |
| ED50 (functional) | = 50 mg kg-1 | The compound was evaluated in vivo for the anticonvulsant activity in quinolinic acid + probenecid seizure model (intravenous), for 5 min drug pretreatment time | ChEMBL. | 1534125 |
| ED50 (functional) | > 50 mg kg-1 | The compound was evaluated in vivo for the anticonvulsant activity in quinolinic acid seizure model (intravenous), for 5 min drug pretreatment time | ChEMBL. | 1534125 |
| ED50 (functional) | = 50 mg kg-1 | The compound was evaluated in vivo for the anticonvulsant activity in quinolinic acid + probenecid seizure model (intravenous), for 5 min drug pretreatment time | ChEMBL. | 1534125 |
| ED50 (functional) | > 100 mg kg-1 | Protection from audiogenic seizure in the DBA/2 mouse 30 min after intraperitoneal administration | ChEMBL. | 8182696 |
| ED50 (functional) | = 100 mg kg-1 | In vivo antagonist activity against seizures elicited by audiogenic administered intra peritoneally in mice | ChEMBL. | 7990104 |
| ED50 (functional) | = 100 mg kg-1 | The compound was evaluated in vivo for the anticonvulsant activity in audiogenic seizure model (intraperitoneal), for 2 hr drug pretreatment time | ChEMBL. | 1534125 |
| ED50 (functional) | > 100 mg kg-1 | Protection from audiogenic seizure in the DBA/2 mouse 30 min after intraperitoneal administration | ChEMBL. | 8182696 |
| ED50 (functional) | = 100 mg kg-1 | In vivo antagonist activity against seizures elicited by audiogenic administered intra peritoneally in mice | ChEMBL. | 7990104 |
| ED50 (functional) | = 100 mg kg-1 | The compound was evaluated in vivo for the anticonvulsant activity in audiogenic seizure model (intraperitoneal), for 2 hr drug pretreatment time | ChEMBL. | 1534125 |
| ED50 (functional) | = 256 mg kg-1 | The compound was evaluated in vivo for the anticonvulsant activity in quinolinic acid seizure model (intraperitoneal), for 2 hr drug pretreatment time | ChEMBL. | 1534125 |
| ED50 (functional) | = 256 mg kg-1 | The compound was evaluated in vivo for the anticonvulsant activity in quinolinic acid seizure model (intraperitoneal), for 2 hr drug pretreatment time | ChEMBL. | 1534125 |
| ED50 (functional) | = 0.09 ug | In vivo antagonist activity against seizures elicited by audiogenic administered icv in mice | ChEMBL. | 7990104 |
| ED50 (functional) | = 0.09 ug | In vivo antagonist activity against seizures elicited by audiogenic administered icv in mice | ChEMBL. | 7990104 |
| IC50 (binding) | = 50 nM | Binding affinity at the glycine binding site of the N-methyl-D-aspartate glutamate receptor in rat cortical membranes using [3H]-dichlorokynurenate ([3H]-DCKA) as radioligand | ChEMBL. | No reference |
| IC50 (binding) | = 50 nM | Binding affinity at the glycine binding site of the N-methyl-D-aspartate glutamate receptor in rat cortical membranes using [3H]-dichlorokynurenate ([3H]-DCKA) as radioligand | ChEMBL. | No reference |
| IC50 (binding) | = 69 nM | Inhibition of the binding of [3H]-L-689,560 ([3H]-4) to the strychnine-insensitive glycine site on rat brain membranes | ChEMBL. | 8182696 |
| IC50 (binding) | = 69 nM | Inhibition of the binding of [3H]-L-689,560 ([3H]-4) to the strychnine-insensitive glycine site on rat brain membranes | ChEMBL. | 8182696 |
| IC50 (binding) | uM | Tested for the ability to inhibit [3H]-MK-801 binding to NMDA receptor of rat cortical membranes in the presence of glutamate (1 microM) : NT denotes not tested | ChEMBL. | No reference |
| IC50 (binding) | 0 uM | Tested for the ability to inhibit [3H]-MK-801 binding to NMDA receptor of rat cortical membranes in the presence of glutamate (1 microM) : NT denotes not tested | ChEMBL. | No reference |
| IC50 (binding) | = 0.07 uM | Inhibition of [3H]-L-689,560 binding to Glycine site of NMDA receptor of rat cortical membranes | ChEMBL. | No reference |
| IC50 (binding) | = 0.07 uM | Inhibition of [3H]-L-689,560 binding to Glycine site of NMDA receptor of rat cortical membranes | ChEMBL. | No reference |
| IC50 (binding) | = 0.14 uM | Inhibition of binding of [3H]-glycine to N-methyl-D-aspartate glutamate receptor 1 from crude synaptic membranes prepared from adult rat cerebral cortex. | ChEMBL. | 9526557 |
| IC50 (binding) | = 0.14 uM | In vitro inhibition of [3H]-Glycine at NMDA receptor | ChEMBL. | 7990104 |
| IC50 (binding) | = 0.14 uM | Activity against rat cortical and hippocampal membrane strychnine-insensitive N-methyl-D-aspartate glutamate receptor 1 using [3H]-gly | ChEMBL. | 2146391 |
| IC50 (binding) | = 0.14 uM | Inhibition of binding of [3H]-glycine to N-methyl-D-aspartate glutamate receptor 1 from crude synaptic membranes prepared from adult rat cerebral cortex. | ChEMBL. | 9526557 |
| IC50 (binding) | = 0.14 uM | In vitro inhibition of [3H]-Glycine at NMDA receptor | ChEMBL. | 7990104 |
| IC50 (binding) | = 0.14 uM | Activity against rat cortical and hippocampal membrane strychnine-insensitive N-methyl-D-aspartate glutamate receptor 1 using [3H]-gly | ChEMBL. | 2146391 |
| IC50 (binding) | = 0.17 uM | Ability to compete with [3H]-glycine for strychnine-insensitive binding sites on rat cortical and hippocampal membrane | ChEMBL. | 1534125 |
| IC50 (binding) | = 0.17 uM | Ability to compete with [3H]-glycine for strychnine-insensitive binding sites on rat cortical and hippocampal membrane | ChEMBL. | 1534125 |
| IC50 (binding) | = 0.21 uM | Inhibitory activity of the compound against Fructose-1,6-bisphosphatase (F16BPase) in rabbit liver | ChEMBL. | 12781194 |
| IC50 (binding) | = 1 uM | Inhibitory activity of the compound against Fructose-1,6-bisphosphatase (F16BPase) in porcine kidney | ChEMBL. | 12781194 |
| IC50 (binding) | = 1 uM | Inhibitory activity of the compound against Fructose-1,6-bisphosphatase (F16BPase) in porcine kidney | ChEMBL. | 12781194 |
| IC50 (binding) | = 2 uM | Inhibition of human recombinant FBPase expressed in Escherichia coli BL21(DE3) by phosphoglucose isomerase and glucose-6-phosphate dehydrogenase coupled assay | ChEMBL. | 24530031 |
| IC50 (binding) | = 2 uM | Inhibition of human liver FBPase expressed in Escherichia coli BL21(DE3) Rosetta cells assessed as reduction of NADP+ to NADPH by phosphoglucose isomerase and glucose-6-phosphate dehydrogenase coupling based spectrophotometry | ChEMBL. | 25461330 |
| IC50 (binding) | = 2.5 uM | Inhibitory activity against Fructose-1,6-bisphosphatase (F16BPase) in human liver | ChEMBL. | 12781194 |
| IC50 (binding) | = 2.5 uM | Inhibition of FBPase (unknown origin) | ChEMBL. | 24530031 |
| IC50 (binding) | = 2.7 uM | Compound was evaluated for in vitro inhibition of cGMP cerebellar slice at NMDA receptor. | ChEMBL. | 7990104 |
| IC50 (binding) | = 2.7 uM | Compound was evaluated for in vitro inhibition of cGMP cerebellar slice at NMDA receptor. | ChEMBL. | 7990104 |
| IC50 (functional) | = 5 uM | Activity was determined by inhibition of glutamate stimulated accumulation of cyclic GMP in neonatal rat cerebral slices. | ChEMBL. | 2146391 |
| IC50 (binding) | = 11 uM | Inhibitory activity of the compound against Fructose-1,6-bisphosphatase (F16BPase) in rat liver | ChEMBL. | 12781194 |
| IC50 (binding) | = 273 uM | The compound was evaluated in vivo for the competitive binding against [3H]-Ionotropic glutamate receptor AMPA for rat cortical and hippocampal membrane glutamate binding site. | ChEMBL. | 1534125 |
| IC50 (binding) | = 273 uM | The compound was evaluated in vivo for the competitive binding against [3H]-Ionotropic glutamate receptor AMPA for rat cortical and hippocampal membrane glutamate binding site. | ChEMBL. | 1534125 |
| IC50 (binding) | = 358 uM | Activity against rat cortical and hippocampal membrane N-methyl-D-aspartate glutamate receptor 1/2A/2B/2C/2D using [3H]-CPP | ChEMBL. | 2146391 |
| IC50 (binding) | = 358 uM | Ability to compete with [3H]-CCP for rat cortical and hippocampal membrane glutamate binding site. | ChEMBL. | 1534125 |
| IC50 (binding) | = 358 uM | Activity against rat cortical and hippocampal membrane N-methyl-D-aspartate glutamate receptor 1/2A/2B/2C/2D using [3H]-CPP | ChEMBL. | 2146391 |
| IC50 (binding) | = 418 uM | The compound was evaluated in vivo for the competitive binding against [3H]-kainate for rat cortical and hippocampal membrane glutamate binding site. | ChEMBL. | 1534125 |
| IC50 (binding) | = 418 uM | The compound was evaluated in vivo for the competitive binding against [3H]-kainate for rat cortical and hippocampal membrane glutamate binding site. | ChEMBL. | 1534125 |
| Kb (functional) | = 1320 nM | Blockade of NMDA-induced depolarizations on rat cortical slices | ChEMBL. | 8182696 |
| Ki (binding) | = 0.14 uM | Tested for the ability to displace [3H]-glycine, by greater than 50%, from NMDA receptor of rat cortical membranes at a dose of 10 microM | ChEMBL. | No reference |
| Ki (binding) | = 0.14 uM | Tested for the ability to displace [3H]-glycine, by greater than 50%, from NMDA receptor of rat cortical membranes at a dose of 10 microM | ChEMBL. | No reference |
| Ki (binding) | = 1.21 uM | Displacement of [3H]PSB-12150 from human GPR17 expressed in CHO-K1 cell membranes after 60 mins by homologous competition binding assay in presence of pranlukast | ChEMBL. | 24900835 |
| Ki (binding) | = 2.32 uM | Displacement of [3H]PSB-12150 from human GPR17 expressed in CHO-K1 cell membranes after 60 mins by competition binding assay | ChEMBL. | 24900835 |
| Ratio (binding) | = 2550 | Selectivity ratio for CPP and gly NMDA binding | ChEMBL. | 2146391 |
| Ratio (binding) | = 2100 CPP/GLY | Ratio of the inhibitory activity against [3H]-CCP for rat cortical and hippocampal membrane glutamate binding site to [3H]-glycine for rat cortical and hippocampal membrane binding site. | ChEMBL. | 1534125 |
| Ratio (binding) | = 2100 CPP/GLY | Ratio of the inhibitory activity against [3H]-CCP for rat cortical and hippocampal membrane glutamate binding site to [3H]-glycine for rat cortical and hippocampal membrane binding site. | ChEMBL. | 1534125 |
| T1/2 (binding) | = 0.3 min | Displacement of [3H]PSB-12150 from human GPR17 expressed in CHO-K1 cell membranes assessed as dissociation half life at 100 uM treated after 1 hr incubation with radioligand by liquid scintillation counting | ChEMBL. | 24900835 |
| T1/2 (binding) | = 1.8 min | Displacement of [3H]PSB-12150 from human GPR17 expressed in CHO-K1 cell membranes assessed as association half life at 100 uM by liquid scintillation counting | ChEMBL. | 24900835 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL31344
- PubChem: 446916
Bibliographic References
9 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.